Zhang Y, Zhao L, Sun Y
NPJ Microgravity. 2024; 10(1):45.
PMID: 38575629
PMC: 10995210.
DOI: 10.1038/s41526-024-00383-7.
Fang L, Tao Y, Che G, Yun Y, Ren M, Liu Y
Mol Med. 2024; 30(1):31.
PMID: 38395742
PMC: 10893653.
DOI: 10.1186/s10020-024-00800-3.
Li X, Zhang C, Lin X, Zhang J, Zhang Y, Yu H
Exp Mol Med. 2024; 56(1):177-191.
PMID: 38177295
PMC: 10834962.
DOI: 10.1038/s12276-023-01142-6.
Boldrini L, Bardi M
Genes (Basel). 2023; 14(8).
PMID: 37628609
PMC: 10454498.
DOI: 10.3390/genes14081558.
Guang Z, Min Z, Jun-Tan L, Tian-Xu D, Xiang G
Front Immunol. 2023; 14:1077003.
PMID: 37033917
PMC: 10077735.
DOI: 10.3389/fimmu.2023.1077003.
Identification of Potential WSB1 Inhibitors by AlphaFold Modeling, Virtual Screening, and Molecular Dynamics Simulation Studies.
Weng Y, Pan C, Shen Z, Chen S, Xu L, Dong X
Evid Based Complement Alternat Med. 2022; 2022:4629392.
PMID: 35600960
PMC: 9122669.
DOI: 10.1155/2022/4629392.
Identification of genes, pathways and transcription factor-miRNA-target gene networks and experimental verification in venous thromboembolism.
Su Y, Li Q, Zheng Z, Wei X, Hou P
Sci Rep. 2021; 11(1):16352.
PMID: 34381164
PMC: 8357955.
DOI: 10.1038/s41598-021-95909-4.
Exosomal miR-1260b derived from non-small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2.
Kim D, Park H, Choi Y, Kang M, Kim T, Pack C
Cell Death Dis. 2021; 12(8):747.
PMID: 34321461
PMC: 8319168.
DOI: 10.1038/s41419-021-04024-9.
Hypoxia-induced Tie1 drives stemness and cisplatin resistance in non-small cell lung carcinoma cells.
Li C, Yang N, Chen Z, Xia N, Shan Q, Wang Z
Cancer Cell Int. 2021; 21(1):57.
PMID: 33461544
PMC: 7814430.
DOI: 10.1186/s12935-020-01729-3.
Development and validation of a prognostic classifier based on HIF-1 signaling for hepatocellular carcinoma.
Deng F, Chen D, Wei X, Lu S, Luo X, He J
Aging (Albany NY). 2020; 12(4):3431-3450.
PMID: 32084009
PMC: 7066907.
DOI: 10.18632/aging.102820.
Mito-Nuclear Communication in Hepatocellular Carcinoma Metabolic Rewiring.
Mello T, Simeone I, Galli A
Cells. 2019; 8(5).
PMID: 31060333
PMC: 6562577.
DOI: 10.3390/cells8050417.
DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system.
Fang J, Ye Z, Gu F, Yan M, Lin Q, Lin J
Oncol Lett. 2018; 16(2):1869-1875.
PMID: 30008878
PMC: 6036466.
DOI: 10.3892/ol.2018.8822.
WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer.
Poujade F, Mannion A, Brittain N, Theodosi A, Beeby E, Leszczynska K
Br J Cancer. 2018; 118(9):1229-1237.
PMID: 29540773
PMC: 5943535.
DOI: 10.1038/s41416-018-0056-3.
A hemoglobin-based oxygen carrier sensitized Cisplatin based chemotherapy in hepatocellular carcinoma.
Qi X, Wong B, Lau S, Ng K, Kwok S, Kin-Wai Sun C
Oncotarget. 2017; 8(49):85311-85325.
PMID: 29156721
PMC: 5689611.
DOI: 10.18632/oncotarget.19672.
Antiangiogenic activity of phthalides-enriched Angelica Sinensis extract by suppressing WSB-1/pVHL/HIF-1α/VEGF signaling in bladder cancer.
Chen M, Hsu W, Chang W, Chou T
Sci Rep. 2017; 7(1):5376.
PMID: 28710377
PMC: 5511260.
DOI: 10.1038/s41598-017-05512-9.
GC7 blocks epithelial-mesenchymal transition and reverses hypoxia-induced chemotherapy resistance in hepatocellular carcinoma cells.
Zhou Q, Tu C, Shao C, Wang W, Zhu J, Cai Y
Am J Transl Res. 2017; 9(5):2608-2617.
PMID: 28560008
PMC: 5446540.
AEG-1 is associated with hypoxia-induced hepatocellular carcinoma chemoresistance via regulating PI3K/AKT/HIF-1alpha/MDR-1 pathway.
Xie Y, Zhong D
EXCLI J. 2017; 15:745-757.
PMID: 28337106
PMC: 5318678.
DOI: 10.17179/excli2016-694.
Homeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies.
Feng Y, Zhou L, Sun X, Li Q
Oncotarget. 2017; 8(12):20452-20461.
PMID: 28107201
PMC: 5386776.
DOI: 10.18632/oncotarget.14723.
WSB1 overcomes oncogene-induced senescence by targeting ATM for degradation.
Kim J, Lee S, Yi S, Han S, Kim S, Lee J
Cell Res. 2016; 27(2):274-293.
PMID: 27958289
PMC: 5339850.
DOI: 10.1038/cr.2016.148.
Hyperglycemia triggers HIPK2 protein degradation.
Baldari S, Garufi A, Granato M, Cuomo L, Pistritto G, Cirone M
Oncotarget. 2016; 8(1):1190-1203.
PMID: 27901482
PMC: 5352047.
DOI: 10.18632/oncotarget.13595.